Amiodarone is a triiodinated antiarrhythmic drug that accumulates in alveolar macrophages. Its use is limited by its high rate of associated pulmonary toxicity, estimated at 5-7%. Radiologic findings for pulmonary toxicity caused by amiodarone are unspecific and varied. The most common finding is subpleural reticular-type interstitial thickening, predominately in the bases of the lungs. However, the presence of parenchymal nodules is an uncommon presentation. We report the case of a woman treated with amiodarone that presented multiple nodular lesions at plain-film radiography and high-resolution CT that were compatible with pulmonary toxicity caused by amiodarone at pathologic examination.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0033-8338(06)73135-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Letermovir should be first-line cytomegalovirus prophylaxis in lung transplant recipients.
Am J Transplant
January 2025
Division of Pulmonary and Critical Care, Hospital of the University of Pennsylvania, Philadelphia, PA.
Universal cytomegalovirus (CMV) prophylaxis is recommended for at-risk lung transplant recipients. Valganciclovir is currently the preferred first-line agent. Valganciclovir-related myelosuppression, however, can lead to drug discontinuation or reduction in anti-metabolite immunosuppression.
View Article and Find Full Text PDFToxicological profile of Acovenoside A as an active pharmaceutical ingredient - prediction of missing key toxicological endpoints using in silico toxicology methodology.
Chem Biol Interact
January 2025
Safety Assessment, Syngene International Limited, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore, 560099, Karnataka, India.
Acovenoside A, a cardenolide glycoside from Acokanthera oppositifolia, demonstrates significant therapeutic potential in cardioprotection and oncology, particularly against non-small cell lung cancer (NSCLC). However, its toxicological profile requires thorough evaluation for safe pharmaceutical application. For this purpose a comprehensive in silico methods were applied, including ACD/Labs Percepta, STopTox, admetSAR 3.
View Article and Find Full Text PDFPharmacological ascorbate combined with rucosopasem selectively radio-chemo-sensitizes NSCLC via generation of HO.
Redox Biol
January 2025
Free Radical and Radiation Biology Program, Department of Radiation Oncology, Holden Comprehensive Cancer Center, The University of Iowa College of Medicine, Iowa City, IA 52242, USA; Interdisciplinary Graduate Program in Human Toxicology, The University of Iowa, Iowa City, IA, 52242, USA.
Differences in cancer and normal cell oxidative metabolism provide a unique therapeutic opportunity for developing combined modality approaches with redox-active small molecules as radio-chemosensitizers that are well-tolerated by normal tissues. Pentaazamacrocyclic Mn (II)-containing (MnPAM) superoxide dismutase (SOD) mimetics and pharmacological ascorbate given IV to achieve [mM] plasma levels (pharmacological ascorbate: P-AscH‾) have been shown to act individually as cancer cell radio- and chemosensitizers via the generation of HOin vivo. The current study shows that the combination of newly developed MnPAM dismutase mimetic, rucosopasem manganese (RUC) with P-AscH‾ radio-sensitizes non-small cell lung cancer cells (NSCLC) and increases steady state levels of intracellular HO with no additional toxicity to normal human bronchial epithelial cells (HBECs).
View Article and Find Full Text PDFAnti-PD-L1 envafolimab combined with anti-VEGF suvemcitug in pretreated solid tumors and hepatocellular carcinoma: an open-label phase II study with safety run-in stage.
Invest New Drugs
January 2025
Department of Internal Medicine, Jilin Cancer Hospital, Changchun, China.
Background: Immune checkpoint inhibitors (ICIs) combined with anti-vascular endothelial growth factor (VEGF) have been the standard first-line treatment of hepatocellular carcinoma (HCC). However, the efficacy of this combination in post-line treatment is still unknown. This study aimed to evaluate the efficacy and safety of the combination of anti-PD-L1 envafolimab and novel humanized anti-VEGF suvemcitug as second-line treatment for patients with HCC.
View Article and Find Full Text PDFMoving towards single fraction peripheral lung stereotactic body radiation therapy: patient care during and after the global COVID-19 pandemic.
Lung Cancer Manag
July 2024
Department of Radiation Oncology, University of Manitoba, Winnipeg, MB, Canada.
Single-fraction stereotactic body radiation therapy (SF-SBRT) for peripheral lung tumors was reviewed. Medically inoperable peripheral lung tumors eligible for SF-SBRT 34 Gray were treated. Patient characteristics, treatment and toxicity parameters were retrospectively collected, and toxicities were evaluated.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!